Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Active-Controlled, Multicenter Phase II Study to Evaluate the Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma

NCT07807007 is registered in ClinicalTrials.gov with Shanghai Xin Huanghe Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07807007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07807007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Active-Controlled, Multicenter Phase II Study to Evaluate the Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma
Lead sponsor
Shanghai Xin Huanghe Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
November 21, 2025
Completion date
August 17, 2026
Enrollment
150 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

asthma